Latest News and Press Releases

TEL AVIV, Israel and RALEIGH, N.C., Nov. 13, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that...

TEL AVIV, Israel and RALEIGH, N.C., Nov. 05, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that...

RedHill obtains Israel rights to Movantik® from AstraZeneca, giving RedHill global rights, excluding Europe and Canada--Movantik approved for opioid-induced constipation in Israel under the brand name...

RedHill has been granted the exclusive right to co-promote Mytesi® (crofelemer 125 mg delayed-release tablets) in the U.S. to certain gastroenterologists and primary care physicians for the approved...

Key Highlights Include: Strong cash position of over $34 million, following completion of a $14.4 million U.S. public offering in February 2015 With three ongoing Phase III clinical...

TEL-AVIV, Israel, Feb. 27, 2014 (GLOBE NEWSWIRE) -- Salix Pharmaceuticals Ltd. (Nasdaq:SLXP) and RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) today announced that they have entered into an...

2013 Key Highlights Include: Strong cash position of over $34 million, as of February 2014, following two private placements in early 2014 and the exercise of warrants, including by directors...